Regaining compliance with NASDAQ's minimum bid price requirement is a significant positive development for Entera Bio Ltd. It removes the immediate risk of delisting, which can be a major concern for investors and can negatively impact stock price and company reputation. Achieving this compliance likely reflects positively on the company's financial health and operational stability, potentially leading to increased investor confidence and a positive short-term impact on the stock price.